Literature DB >> 33505223

The Inherent Unfairness of COVID-19 Drug Access Pathways.

Kayte Spector-Bagdady1, Misty Gravelin2, Kevin J Weatherwax2, Andrew G Shuman1.   

Abstract

Entities:  

Year:  2020        PMID： 33505223      PMCID： PMC7837294          DOI： 10.1080/15265161.2020.1795546

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN： 1526-5161            Impact factor:   11.229


× No keyword cloud information.
  4 in total

1.  Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy.

Authors:  Alex John London; Jonathan Kimmelman
Journal:  Hastings Cent Rep       Date:  2019-07       Impact factor: 2.683

2.  The Critical Role of Medical Institutions in Expanding Access to Investigational Interventions.

Authors:  Kayte Spector-Bagdady; Kevin J Weatherwax; Misty Gravelin; Andrew G Shuman
Journal:  Hastings Cent Rep       Date:  2019-03       Impact factor: 2.683

Review 3.  Current pharmacological treatments for COVID-19: What's next?

Authors:  Cristina Scavone; Simona Brusco; Michele Bertini; Liberata Sportiello; Concetta Rafaniello; Alice Zoccoli; Liberato Berrino; Giorgio Racagni; Francesco Rossi; Annalisa Capuano
Journal:  Br J Pharmacol       Date:  2020-05-15       Impact factor: 8.739
  4 in total
  1 in total

1.  Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies.

Authors:  Kayte Spector-Bagdady; Holly Fernandez Lynch; Barbara E Bierer; Luke Gelinas; Sara Chandros Hull; David Magnus; Michelle N Meyer; Richard R Sharp; Jeremy Sugarman; Benjamin S Wilfond; Ruqaiijah Yearby; Seema Mohapatra
Journal:  Hastings Cent Rep       Date:  2021-12-15       Impact factor: 4.298
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.